Form 8-K - Current report:
SEC Accession No. 0001213900-25-010525
Filing Date
2025-02-05
Accepted
2025-02-05 16:00:25
Documents
13
Period of Report
2025-02-04
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0229970-8k_oruka.htm   iXBRL 8-K 30306
  Complete submission text file 0001213900-25-010525.txt   204099

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE orka-20250204.xsd EX-101.SCH 3012
3 XBRL LABEL FILE orka-20250204_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE orka-20250204_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0229970-8k_oruka_htm.xml XML 3678
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 25593122
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)